J
JW Bio
Specialized biotechnology for diagnostic reagents and medical devices
About JW Bio
JW Bioscience is a South Korean company specializing in the development and manufacturing of in-vitro diagnostic reagents and medical equipment. The company is a subsidiary of JW Life Science and part of the larger JW Group, a global healthcare company. JW Bioscience was officially established in 2016.
The company's business is segmented into two main areas: diagnostic solutions and medical devices. In the diagnostics field, JW Bioscience is focused on creating technologies for early disease detection, securing patents for biomarkers related to pancreatic cancer and sepsis. It develops immunoassay analyzers and reagents for diagnosing conditions like cancer and infectious diseases. A significant part of its strategy involves expanding its presence in the diagnostic reagent market through partnerships, such as an exclusive supply agreement with China's BIOELAB for fully automated biochemical analyzers in Korea. The company also develops point-of-care (POCT) testing devices, like the 'JWelix Q6' high-sensitivity analyzer, designed to deliver rapid results from blood samples.
In addition to diagnostics, JW Bioscience manufactures a diverse range of medical equipment aimed at localizing and advancing the medical device industry in Korea. Its product portfolio includes digital X-ray machines, LED surgical lights, operating tables, infant incubators, and sterilizers. Many of these products have received international certifications such as CE and ISO, enabling their export to markets in Europe, China, and the Middle East.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2002
- Headquarters
- South Korea
- Open positions
- None listed
- Dealroom signal
- 14.3/100
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Nov 2016 | $42M | $168M | KB Securities · Mirae Asset Sekuritas | — |
Growth signals
Latest recorded traffic for JW Bio is 1.3K monthly website visits, up 8.3% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
KB Securities- MSMirae Asset Sekuritas
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about JW Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See JW Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.